Compass Therapeutics Inc. reports results for the quarter ended March 31 - Earnings Summary

• Compass Therapeutics Inc. CMPX.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -8 cents. The mean expectation of ten analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -15 cents to -5 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Compass Therapeutics Inc.'s reported EPS for the quarter was a loss of 12 cents​.

• The company reported a quarterly loss of $16.63 million.

• Compass Therapeutics Inc. shares had fallen by 4.2% this quarter and gained 25.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 23.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

• Wall Street's median 12-month price target for Compass Therapeutics Inc. is $10.00

This summary was machine generated from LSEG data May 12 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)